The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review

Keyphrases

• Alzheimer's Disease 100%
• Positron Emission Tomography 100%
• Central Nervous System 100%
• Amyloid Plaques 100%
• Plaque 100%
• Alzheimer's Disease Pathology 100%
• Plasma Amyloid-β 100%
• Affinity Purification-mass Spectrometry (AP-MS) 100%
• Alzheimer's Disease Diagnosis 100%
• Cerebrospinal Fluid 50%
• Clinical Trials 50%
• Amino Acids 50%
• Medical Center 50%
• Amyloid beta 50%
• Minimally Invasive Procedures 50%
• Amyloid Burden 50%
• Disease-modifying Therapy 50%
• Brain Amyloid 50%
• Blood Biomarkers 50%
• Clinical Assessment 50%
• Immunoassay 50%
• Amyloid Positron Emission Tomography 50%
• Amyloidosis 50%
• Cerebrospinal Fluid Analysis 50%
• Medical Insurance 50%
• Amyloid Status 50%
• Specialty Clinic 50%
• Amyloid Aggregates 50%
• Protofibrils 50%

Medicine and Dentistry

• Alzheimer's Disease 100%
• Amyloid Plaque 100%
• Amyloid Beta 100%
• Amyloid Protein 80%
• Positron Emission Tomography 60%
• Diagnosis 40%
• Central Nervous System 40%
• Mass Spectrum 40%
• Immunoprecipitation 40%
• Biological Marker 20%
• Health Care Cost 20%
• Cerebrospinal Fluid 20%
• Clinical Trial 20%
• Immunoassay 20%
• Minimally Invasive Procedure 20%
• Disease Modifying Therapy 20%
• Amino Acid 20%
• Clinical Assessment 20%
• Amyloidosis 20%
• Cerebrospinal Fluid Analysis 20%
• Pathology of Alzheimer's Disease 20%
• Oligomer 20%

Immunology and Microbiology

• Blood Plasma 100%
• Positron Emission Tomography 100%
• Cerebrospinal Fluid 66%
• Immunoprecipitation 66%
• Central Nervous System 66%
• Immunoassay 33%
• Amyloidosis 33%
• Peptides 33%
• Amino Acid 33%